Last reviewed · How we verify
Sci B vac
At a glance
| Generic name | Sci B vac |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults (PHASE3)
- Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B® (PHASE3)
- A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™ (PHASE4)
- Lot-to-lot Consistency of Sci-B-Vac™ in Adults (PHASE3)
- Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults (PHASE3)
- Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease (NA)
- ID HBV Vaccination With Imiquimod in OBI (PHASE2, PHASE3)
- Efficacy and Safety of Hepatitis B Vaccine in Chronic Kidney Disease Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sci B vac CI brief — competitive landscape report
- Sci B vac updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI